Molecular Basis for the Regulation of Angiogenesis by Thrombospondin-1 and-2

被引:371
作者
Lawler, Patrick R. [1 ]
Lawler, Jack [2 ,3 ]
机构
[1] McGill Univ, Dept Med, Ctr Hlth, Montreal, PQ H3G 1Y6, Canada
[2] Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA
[3] Harvard Univ, Sch Med, Boston, MA 02215 USA
来源
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE | 2012年 / 2卷 / 05期
基金
美国国家卫生研究院;
关键词
NITRIC-OXIDE SYNTHASE; ENDOTHELIAL GROWTH-FACTOR; REPEATS RECOMBINANT PROTEIN; EPITHELIAL OVARIAN-CANCER; TUMOR-GROWTH; TYPE-1; REPEATS; INHIBITOR ABT-510; PROGENITOR CELLS; IN-VITRO; METRONOMIC CHEMOTHERAPY;
D O I
10.1101/cshperspect.a006627
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Thrombospondins TSP-1 and TSP-2 are potent endogenous inhibitors of angiogenesis. They inhibit angiogenesis through direct effects on endothelial cell migration, proliferation, survival, and apoptosis and by antagonizing the activity of VEGF. Several of the membrane receptor systems and signal transduction molecules that mediate the effects of TSP-1 and TSP-2 have been elucidated. TSP-1 and TSP-2 exert their direct effects through CD36, CD47, and integrins. Recent data indicate that CD36 and beta 1 integrins collaborate to transmit the signals that are initiated by TSP-1 and TSP-2. Furthermore, these receptors appear to associate with VEGFR2 to form a platform for the integration of positive and negative signals for angiogenesis. Cross talk between pro- and antiangiogenic signal transduction pathways may enable TSP-1 and TSP-2 to inhibit angiogenesis byantagonizing survival pathways while also activating apoptotic pathways. CD36 and CD47 are both involved in the suppression of nitric oxide (NO). Advances in understanding of the molecular regulation of angiogenesis by TSP have paved the way for innovations in experimental treatment of cancers and will likely continue to offer vast avenues for discovery in other disease processes as well.
引用
收藏
页数:13
相关论文
共 95 条
[21]   Life history of eNOS: Partners and pathways [J].
Dudzinski, David M. ;
Michel, Thomas .
CARDIOVASCULAR RESEARCH, 2007, 75 (02) :247-260
[22]  
Ebbinghaus S, 2007, CLIN CANCER RES, V13, P6689
[23]  
Ferrari do Outeiro-Bernstein MA, 2002, MATRIX BIOL, V21, P311
[24]  
FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182
[25]   Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability [J].
Fukumura, D ;
Gohongi, T ;
Kadambi, A ;
Izumi, Y ;
Ang, J ;
Yun, CO ;
Buerk, DG ;
Huang, PL ;
Jain, RK .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (05) :2604-2609
[26]   Integrin-associated protein is a receptor for the C-terminal domain of thrombospondin [J].
Gao, AG ;
Lindberg, FP ;
Finn, MB ;
Blystone, SD ;
Brown, EJ ;
Frazier, WA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (01) :21-24
[27]   A TUMOR SUPPRESSOR-DEPENDENT INHIBITOR OF ANGIOGENESIS IS IMMUNOLOGICALLY AND FUNCTIONALLY INDISTINGUISHABLE FROM A FRAGMENT OF THROMBOSPONDIN [J].
GOOD, DJ ;
POLVERINI, PJ ;
RASTINEJAD, F ;
LEBEAU, MM ;
LEMONS, RS ;
FRAZIER, WA ;
BOUCK, NP .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (17) :6624-6628
[28]   A Phase 1 Trial of 2 Dose Schedules of ABT-510, an Antiangiogenic, Thrombospondin-1-mimetic Peptide, in Patients With Advanced Cancer [J].
Gordon, Michael S. ;
Mendelson, David ;
Carr, Robert ;
Knight, Raymond A. ;
Humerickhouse, Rod A. ;
Iannone, Maria ;
Stopeck, Alison T. .
CANCER, 2008, 113 (12) :3420-3429
[29]   Thrombospondin-1 inhibits VEGF levels in the ovary directly by binding and internalization via the low density lipoprotein receptor-related protein-1 (LRP-1) [J].
Greenaway, James ;
Lawler, Jack ;
Moorehead, Roger ;
Bornstein, Paul ;
Lamarre, Jonathan ;
Petrik, Jim .
JOURNAL OF CELLULAR PHYSIOLOGY, 2007, 210 (03) :807-818
[30]   ABT-510 induces tumor cell apoptosis and inhibits ovarian tumor growth in an orthotopic, syngeneic model of epithelial ovarian cancer [J].
Greenaway, James ;
Henkin, Jack ;
Lawler, Jack ;
Moorehead, Roger ;
Petrik, Jim .
MOLECULAR CANCER THERAPEUTICS, 2009, 8 (01) :64-74